SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    C. Melchior, G. Gourcerol, N. Chastan, E. Verin, J. F. Menard, P. Ducrotte, A. M. Leroi, Effect of transcranial magnetic stimulation on rectal sensitivity in irritable bowel syndrome: a randomized, placebo-controlled pilot study, Colorectal Disease, 2014, 16, 3
  2. 2
    Klaus Bielefeldt, G.F. Gebhart, Practical Management of Pain, 2014,

    CrossRef

  3. 3
    D. Bouhassira, X. Moisset, P. Jouet, H. Duboc, B. Coffin, J.-M. Sabate, Changes in the modulation of spinal pain processing are related to severity in irritable bowel syndrome, Neurogastroenterology & Motility, 2013, 25, 7
  4. You have free access to this content4
    J. Matricon, M. Meleine, A. Gelot, T. Piche, M. Dapoigny, E. Muller, D. Ardid, Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome, Alimentary Pharmacology & Therapeutics, 2012, 36, 11-12
  5. You have free access to this content5
    J. Tack, M. Camilleri, L. Chang, W. D. Chey, J. J. Galligan, B. E. Lacy, S. Müller-Lissner, E. M. M. Quigley, J. Schuurkes, J. H. Maeyer, V. Stanghellini, Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders, Alimentary Pharmacology & Therapeutics, 2012, 35, 7
  6. 6
    Jae Woong Lee, Ki Woon Sung, Oh Young Lee, Seo Eun Lee, Chong Il Sohn, The Effects of 5-HT4 Receptor Agonist, Mosapride Citrate, on Visceral Hypersensitivity in a Rat Model, Digestive Diseases and Sciences, 2012, 57, 6, 1517

    CrossRef

  7. 7
    Richard J. Saad, Peripherally Acting Therapies for the Treatment of Irritable Bowel Syndrome, Gastroenterology Clinics of North America, 2011, 40, 1, 163

    CrossRef

  8. 8
    S. M. O’mahony, D. C. Bulmer, A.-m. Coelho, P. Fitzgerald, C. Bongiovanni, K. Lee, W. Winchester, T. G. Dinan, J. F. Cryan, 5-HT2B receptors modulate visceral hypersensitivity in a stress-sensitive animal model of brain-gut axis dysfunction, Neurogastroenterology & Motility, 2010, 22, 5
  9. 9
    Silvia Suffredini, Elisabetta Cerbai, Gabriele Giunti, Mohamed El Mouelhi, Hans-Jürgen Pfannkuche, Alessadro Mugelli, Electrophysiological Characterization of Isolated Human Atrial Myocytes Exposed to Tegaserod, Basic & Clinical Pharmacology & Toxicology, 2010, 106, 5
  10. 10
    Yong Sung Kim, Suck Chei Choi, Jae Myung Park, Chang Hwan Choi, Dong Ho Lee, Hee Jung Son, In Kyung Sung, Jeong Jo Jeong, Joon Seong Lee, Ki Nam Shim, Kwang Jae Lee, Su Jin Hong, Myung-Gyu Choi, IBS Club of the Korean Society of Neurogastroenterology, The Effect of Tegaserod on Symptoms and Quality of Life in Korean Women with Irritable Bowel Syndrome with Constipation, Journal of Neurogastroenterology and Motility, 2010, 16, 1, 61

    CrossRef

  11. 11
    Hui-Rong Liu, Xiao-Mei Wang, En-Hua Zhou, Yin Shi, Na Li, Ling-Song Yuan, Huan-Gan Wu, Acupuncture at Both ST25 and ST37 Improves the Pain Threshold of Chronic Visceral Hypersensitivity Rats, Neurochemical Research, 2009, 34, 11, 1914

    CrossRef

  12. 12
    Charles H. Knowles, Qasim Aziz, Basic and clinical aspects of gastrointestinal pain, Pain, 2009, 141, 3, 191

    CrossRef

  13. 13
    A. V. Emmanuel, J. Tack, E. M. Quigley, N. J. Talley, Pharmacological management of constipation, Neurogastroenterology & Motility, 2009, 21,
  14. 14
    L. Van Oudenhove, B. Geeraerts, J. Tack, Limitations of current paradigms for visceral sensitivity testing, Neurogastroenterology & Motility, 2008, 20, 2
  15. 15
    Trinh T. Truong, Bruce D. Naliboff, Lin Chang, Novel techniques to study visceral hypersensitivity in irritable bowel syndrome, Current Gastroenterology Reports, 2008, 10, 4, 369

    CrossRef

  16. 16
    C. D. Ericsson, C. Hatz, A. W. DuPont, Postinfectious Irritable Bowel Syndrome, Clinical Infectious Diseases, 2008, 46, 4, 594

    CrossRef

  17. 17
    J.-m. Sabaté, D. Bouhassira, C. Poupardin, A. Wagner, Y. Loria, B. Coffin, Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation, Neurogastroenterology & Motility, 2008, 20, 2
  18. 18
    D. T. Beattie, J. A. M. Smith, Serotonin pharmacology in the gastrointestinal tract: a review, Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 377, 3, 181

    CrossRef

  19. 19
    William D. Chey, Pierre Paré, Andrea Viegas, Gregory Ligozio, Michael A. Shetzline, Tegaserod for Female Patients Suffering From IBS With Mixed Bowel Habits or Constipation: A Randomized Controlled Trial, The American Journal of Gastroenterology, 2008, 103, 5, 1217

    CrossRef

  20. 20
    Nimish Vakil, Loren Laine, Nicholas J. Talley, Salam F. Zakko, Jan Tack, William D. Chey, Jeffrey Kralstein, David L. Earnest, Gregory Ligozio, Marielle Cohard-Radice, Tegaserod Treatment for Dysmotility-Like Functional Dyspepsia: Results of Two Randomized, Controlled Trials, The American Journal of Gastroenterology, 2008, ???

    CrossRef

  21. 21
    Olivia Liem, Hayat M Mousa, Marc A Benninga, Carlo Di Lorenzo, Tegaserod Use in Children: A Single-center Experience, Journal of Pediatric Gastroenterology and Nutrition, 2008, 46, 1, 54

    CrossRef

  22. 22
    J. A. M. Smith, D. T. Beattie, D. Marquess, J.-P. Shaw, R. G. Vickery, P. P. A. Humphrey, The in vitro pharmacological profile of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity, Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 378, 1, 125

    CrossRef

  23. 23
    Klaus Bielefeldt, G.F. Gebhart, Raj's Practical Management of Pain, 2008,

    CrossRef

  24. 24
    B. Coffin, Douleurs et syndrome de l’intestin irritable : prise en charge thérapeutique à la lumière des nouvelles pistes physiopathologiques, Côlon & Rectum, 2007, 1, 3, 184

    CrossRef

  25. 25
    Michael Fried, John F. Johanson, Kok Ann Gwee, Amy Wagner, Eckhard Pecher, Peter Rueegg, Efficacy of Tegaserod in Chronic Constipation in Men, The American Journal of Gastroenterology, 2007, 102, 2, 362

    CrossRef

  26. 26
    Elizabeth J. Videlock, Lin Chang, Irritable Bowel Syndrome: Current Approach to Symptoms, Evaluation, and Treatment, Gastroenterology Clinics of North America, 2007, 36, 3, 665

    CrossRef

  27. 27
    S. Kindt, J. Tack, Mechanisms of serotonergic agents for treatment of gastrointestinal motility and functional bowel disorders, Neurogastroenterology & Motility, 2007, 19,
  28. 28
    Olivia Liem, Marc A. Benninga, Hayat M. Mousa, Carlo Di Lorenzo, Novel and alternative therapies for childhood constipation, Current Gastroenterology Reports, 2007, 9, 3, 214

    CrossRef

  29. 29
    Andrew W. DuPont, Post-infectious irritable bowel syndrome, Current Gastroenterology Reports, 2007, 9, 5, 378

    CrossRef

  30. 30
    Kwong M Fock, Amy Wagner, Safety, tolerability and satisfaction with tegaserod therapy in Asia–Pacific patients with irritable bowel syndrome with constipation, Journal of Gastroenterology and Hepatology, 2007, 22, 8
  31. 31
    L. Bueno, F. De Ponti, M. Fried, G. A. Kullak-ublick, M. A. Kwiatek, D. Pohl, E. M. M. Quigley, J. Tack, N. J. Talley, Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity, Neurogastroenterology & Motility, 2007, 19,
  32. 32
    Peter Layer, Jutta Keller, Helena Loeffler, Andreas Kreiss, Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom, Therapeutics and Clinical Risk Management, 2007, 3, 1, 107

    CrossRef

  33. 33
    Michael D. Gershon, Jan Tack, The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders, Gastroenterology, 2007, 132, 1, 397

    CrossRef

  34. 34
    B. Greenwood-van Meerveld, K. Venkova, G. Hicks, E. Dennis, M. D. Crowell, Activation of peripheral 5-HT4 receptors attenuates colonic sensitivity to intraluminal distension, Neurogastroenterology & Motility, 2006, 18, 1
  35. 35
    Howard Y. Chang, Eoin C. Kelly, Anthony J. Lembo, Current gut-directed therapies for irritable bowel syndrome, Current Treatment Options in Gastroenterology, 2006, 9, 4, 314

    CrossRef

  36. 36
    C. Ng, A. Malcolm, R. Hansen, J. E. Kellow, Distension technique influences the relationship between colonic and rectal hypersensitivity in irritable bowel syndrome, Neurogastroenterology & Motility, 2006, 18, 3
  37. 37
    N. J. TALLEY, M. CAMILLERI, D. BURTON, G. THOMFORDE, K. KOCH, M. J. RUCKER, J. PETERSON, A. R. ZINSMEISTER, D. L. EARNEST, Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers, Alimentary Pharmacology & Therapeutics, 2006, 24, 5
  38. 38
    Lucinda A Harris, Lin Chang, Irritable bowel syndrome: new and emerging therapies, Current Opinion in Internal Medicine, 2006, 5, 3, 297

    CrossRef

  39. 39
    Michael Camilleri, Lionel Bueno, Fabrizio de Ponti, Jean Fioramonti, R. Bruce Lydiard, Jan Tack, Pharmacological and Pharmacokinetic Aspects of Functional Gastrointestinal Disorders, Gastroenterology, 2006, 130, 5, 1421

    CrossRef

  40. 40
    Eamonn M.M. Quigley, Arnold Wald, James Fidelholtz, Michel Boivin, Eckhard Pecher, David Earnest, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation: Pooled Data From Two Phase III Studies, Clinical Gastroenterology and Hepatology, 2006, 4, 5, 605

    CrossRef

  41. 41
    Anurag Agrawal, Peter Whorwell, Tegaserod in the treatment of constipation-predominant functional gastrointestinal disorders, Therapy, 2006, 3, 4, 475

    CrossRef

  42. 42
    Anurag Agrawal, Peter Whorwell, Tegaserod in the treatment of constipation-predominant functional gastrointestinal disorders, Therapy, 2006, 3, 4, 475

    CrossRef

  43. 43
    Richard Saad, William D Chey, Tegaserod in the treatment of irritable bowel syndrome with constipation, Women's Health, 2006, 2, 1, 29

    CrossRef

  44. 44
    John McLaughlin, Lesley A Houghton, The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome, Expert Opinion on Drug Safety, 2006, 5, 2, 313

    CrossRef

  45. 45
    Michael Camilleri, Chronic Abdominal and Visceral Pain, 2006,

    CrossRef

  46. 46
    Peter Holzer, Chronic Abdominal and Visceral Pain, 2006,

    CrossRef

  47. 47
    Benoit Coffin, Jean-Marc Sabaté, Didier Bouhassira, Douleurs et syndrome de l’intestin irritable, Gastroentérologie Clinique et Biologique, 2005, 29, 8-9, 769

    CrossRef

  48. 48
    Michael D Gershon, Nerves, Reflexes, and the Enteric Nervous System, Journal of Clinical Gastroenterology, 2005, 39, Supplement 3, S184

    CrossRef

  49. 49
    Michael Camilleri, Pharmacogenomics and functional gastrointestinal disorders, Pharmacogenomics, 2005, 6, 5, 491

    CrossRef

  50. 50
    Lin Zhu, Research strategy and clinical significance of anorectum manometry, Journal of Chinese Integrative Medicine, 2005, 3, 3, 240

    CrossRef

  51. 51
    S. D. Kuiken, G. N. Tytgat, G. E. Boeckxstaens, Review article: drugs interfering with visceral sensitivity for the treatment of functional gastrointestinal disorders – the clinical evidence, Alimentary Pharmacology & Therapeutics, 2005, 21, 6
  52. 52
    Michael A. Kamm, Stefan Muller-Lissner, Nicholas J. Talley, Jan Tack, Guy Boeckxstaens, Oleg N. Minushkin, Andrey Kalinin, Jan Dzieniszewski, Peter Haeck, Fiona Fordham, Sophie Hugot-Cournez, Brigitte Nault, Tegaserod for the Treatment of Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled Multinational Study, The American Journal of Gastroenterology, 2005, 100, 2, 362

    CrossRef

  53. 53
    John K. DiBaise, Tegaserod-Associated Ischemic Colitis, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2005, 25, 4
  54. 54
    Peter Layer, Jutta Keller, Stefan Mueller-Lissner, Peter Rüegg, Helena Loeffler, Tegaserod: Long-Term Treatment for Irritable Bowel Syndrome Patients with Constipation in Primary Care, Digestion, 2005, 71, 4, 238

    CrossRef

  55. 55
    Giorgio Sandrini, Mariano Serrao, Paolo Rossi, Antonietta Romaniello, Giorgio Cruccu, Jean Claude Willer, The lower limb flexion reflex in humans, Progress in Neurobiology, 2005, 77, 6, 353

    CrossRef

  56. 56
    Filippo Cremonini, Nicholas J Talley, Treatments targeting putative mechanisms in irritable bowel syndrome, Nature Clinical Practice Gastroenterology & Hepatology, 2005, 2, 2, 82

    CrossRef

  57. 57
    Richard Lea, Peter J Whorwell, Benefit-Risk Assessment of Tegaserod in Irritable Bowel Syndrome, Drug Safety, 2004, 27, 4, 229

    CrossRef

  58. 58
    John F. Johanson, Arnold Wald, Gervais Tougas, William D. Chey, James S. Novick, Anthony J. Lembo, Fiona Fordham, Mary Guella, Brigitte Nault, Effect of tegaserod in chronic constipation: A randomized, double-blind, controlled trial, Clinical Gastroenterology and Hepatology, 2004, 2, 9, 796

    CrossRef

  59. 59
    Peter Holzer, Gastrointestinal pain in functional bowel disorders: sensory neurons as novel drug targets, Expert Opinion on Therapeutic Targets, 2004, 8, 2, 107

    CrossRef

  60. 60
    E. L. Calvert, P. J. Whorwell, L. A. Houghton, Inter-digestive and post-prandial antro-pyloro-duodenal motor activity in humans: effect of 5-hydroxytryptamine 1 receptor agonism, Alimentary Pharmacology & Therapeutics, 2004, 19, 7
  61. 61
    D. Lesbros-Pantoflickova, P. Michetti, M. Fried, C. Beglinger, A. L. Blum, Meta-analysis: the treatment of irritable bowel syndrome, Alimentary Pharmacology & Therapeutics, 2004, 20, 11-12
  62. 62
    J. F. Johanson, Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies, Neurogastroenterology & Motility, 2004, 16, 6
  63. 63
    A. Perelló, F. Mearin, Posibilidades farmacológicas de modulación de la percepción visceral, Gastroenterología y Hepatología, 2004, 27, 8, 480

    CrossRef

  64. 64
    M. D. Gershon, Review article: serotonin receptors and transporters — roles in normal and abnormal gastrointestinal motility, Alimentary Pharmacology & Therapeutics, 2004, 20,
  65. 65
    P. Schoenfeld, Review article: the safety profile of tegaserod, Alimentary Pharmacology & Therapeutics, 2004, 20,
  66. 66
    Sonal Patel, Driss Berrada, Anthony Lembo, Review of tegaserod in the treatment of irritable bowel syndrome, Expert Opinion on Pharmacotherapy, 2004, 5, 11, 2369

    CrossRef

  67. 67
    Michael D Crowell, Role of serotonin in the pathophysiology of the irritable bowel syndrome, British Journal of Pharmacology, 2004, 141, 8
  68. 68
    William L Hasler, Philip Schoenfeld, Safety Profile of Tegaserod, a 5-HT4 Receptor Agonist, for the Treatment of Irritable Bowel Syndrome, Drug Safety, 2004, 27, 9, 619

    CrossRef

  69. 69
    P. Schoenfeld, Systematic review: incidence of abdominal/pelvic surgery amongst patients using tegaserod in randomized controlled trials, Alimentary Pharmacology & Therapeutics, 2004, 19, 3
  70. 70
    D T Beattie, J A M Smith, D Marquess, R G Vickery, S R Armstrong, T Pulido-Rios, J L McCullough, C Sandlund, C Richardson, N Mai, P P A Humphrey, The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo, British Journal of Pharmacology, 2004, 143, 5
  71. 71
    Karen Bergmann, Letters to the Editor, Journal of Clinical Pharmacy and Therapeutics, 2003, 28, 2
  72. 72
    Antona J Wagstaff, James E Frampton, Katherine F Croom, Tegaserod, Drugs, 2003, 63, 11, 1101

    CrossRef

  73. 73
    Elizabeth J. Videlock, Lin Chang, Irritable Bowel Syndrome,